JP2012105686A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012105686A5 JP2012105686A5 JP2012054494A JP2012054494A JP2012105686A5 JP 2012105686 A5 JP2012105686 A5 JP 2012105686A5 JP 2012054494 A JP2012054494 A JP 2012054494A JP 2012054494 A JP2012054494 A JP 2012054494A JP 2012105686 A5 JP2012105686 A5 JP 2012105686A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- combination
- sirna
- modification
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020004459 Small interfering RNA Proteins 0.000 claims 17
- 230000004048 modification Effects 0.000 claims 13
- 238000012986 modification Methods 0.000 claims 13
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 6
- 125000002652 ribonucleotide group Chemical group 0.000 claims 6
- 108091028664 Ribonucleotide Proteins 0.000 claims 5
- 239000002336 ribonucleotide Substances 0.000 claims 5
- 239000003446 ligand Substances 0.000 claims 4
- 102000005962 receptors Human genes 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 3
- 235000012000 cholesterol Nutrition 0.000 claims 3
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 2
- 239000003529 anticholesteremic agent Substances 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 102000007330 LDL Lipoproteins Human genes 0.000 claims 1
- 108010007622 LDL Lipoproteins Proteins 0.000 claims 1
- 102000006382 Ribonucleases Human genes 0.000 claims 1
- 108010083644 Ribonucleases Proteins 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 229940104302 cytosine Drugs 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 210000005229 liver cell Anatomy 0.000 claims 1
- -1 methoxyethyl Chemical group 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 150000003230 pyrimidines Chemical class 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 229940035893 uracil Drugs 0.000 claims 1
- 230000029812 viral genome replication Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61495504P | 2004-10-01 | 2004-10-01 | |
| US60/614,955 | 2004-10-01 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007534866A Division JP2008514242A (ja) | 2004-10-01 | 2005-09-30 | 改変型の小さい干渉ｒｎａ分子および使用方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012193264A Division JP2012255024A (ja) | 2004-10-01 | 2012-09-03 | 改変型の小さい干渉ｒｎａ分子および使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012105686A JP2012105686A (ja) | 2012-06-07 |
| JP2012105686A5 true JP2012105686A5 (2) | 2012-11-01 |
Family
ID=36143139
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007534866A Pending JP2008514242A (ja) | 2004-10-01 | 2005-09-30 | 改変型の小さい干渉ｒｎａ分子および使用方法 |
| JP2012054494A Pending JP2012105686A (ja) | 2004-10-01 | 2012-03-12 | 改変型の小さい干渉ｒｎａ分子および使用方法 |
| JP2012193264A Pending JP2012255024A (ja) | 2004-10-01 | 2012-09-03 | 改変型の小さい干渉ｒｎａ分子および使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007534866A Pending JP2008514242A (ja) | 2004-10-01 | 2005-09-30 | 改変型の小さい干渉ｒｎａ分子および使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012193264A Pending JP2012255024A (ja) | 2004-10-01 | 2012-09-03 | 改変型の小さい干渉ｒｎａ分子および使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8138161B2 (2) |
| EP (1) | EP1796732B1 (2) |
| JP (3) | JP2008514242A (2) |
| CA (1) | CA2581651C (2) |
| ES (1) | ES2441791T3 (2) |
| WO (1) | WO2006039656A2 (2) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10131904B2 (en) | 2008-02-11 | 2018-11-20 | Rxi Pharmaceuticals Corporation | Modified RNAi polynucleotides and uses thereof |
| US8815818B2 (en) | 2008-07-18 | 2014-08-26 | Rxi Pharmaceuticals Corporation | Phagocytic cell delivery of RNAI |
| CA2746527A1 (en) * | 2008-09-22 | 2010-03-25 | Rxi Pharmaceuticals Corporation | Rna interference in skin indications |
| WO2010059226A2 (en) | 2008-11-19 | 2010-05-27 | Rxi Pharmaceuticals Corporation | Inhibition of map4k4 through rnai |
| US9493774B2 (en) | 2009-01-05 | 2016-11-15 | Rxi Pharmaceuticals Corporation | Inhibition of PCSK9 through RNAi |
| US9745574B2 (en) | 2009-02-04 | 2017-08-29 | Rxi Pharmaceuticals Corporation | RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
| CN106074591B (zh) | 2010-03-24 | 2020-01-14 | 菲奥医药公司 | 眼部症候中的rna干扰 |
| US9080171B2 (en) | 2010-03-24 | 2015-07-14 | RXi Parmaceuticals Corporation | Reduced size self-delivering RNAi compounds |
| BR112012024049A2 (pt) | 2010-03-24 | 2017-03-01 | Rxi Pharmaceuticals Corp | interferência de rna em indicações dérmicas e fibróticas |
| WO2012024170A2 (en) * | 2010-08-17 | 2012-02-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| WO2015084897A2 (en) | 2013-12-02 | 2015-06-11 | Mirimmune, Llc | Immunotherapy of cancer |
| US11279934B2 (en) | 2014-04-28 | 2022-03-22 | Phio Pharmaceuticals Corp. | Methods for treating cancer using nucleic acids targeting MDM2 or MYCN |
| KR102506169B1 (ko) | 2014-09-05 | 2023-03-08 | 피오 파마슈티칼스 코프. | Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법 |
| GB201418135D0 (en) * | 2014-10-14 | 2014-11-26 | London School Hygiene & Tropical Medicine | Anti-viral agent |
| US10808247B2 (en) | 2015-07-06 | 2020-10-20 | Phio Pharmaceuticals Corp. | Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach |
| CN108135923B (zh) | 2015-07-06 | 2021-03-02 | 菲奥医药公司 | 靶向超氧化物歧化酶1（sod1）的核酸分子 |
| US20170137821A1 (en) | 2015-07-17 | 2017-05-18 | Arcturus Therapeutics, Inc. | Molecules and agents for treating hepatitis b virus |
| JP6924744B2 (ja) | 2015-07-17 | 2021-08-25 | アークトゥラス・セラピューティクス・インコーポレイテッドＡｒｃｔｕｒｕｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | Ｂ型肝炎ウイルスに対する組成物および薬剤ならびにその使用 |
| WO2017070151A1 (en) | 2015-10-19 | 2017-04-27 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering nucleic acid compounds targeting long non-coding rna |
| EP4035659A1 (en) | 2016-11-29 | 2022-08-03 | PureTech LYT, Inc. | Exosomes for delivery of therapeutic agents |
| WO2018195355A1 (en) | 2017-04-19 | 2018-10-25 | Rxi Pharmaceuticals Corporation | Topical delivery of nucleic acid compounds |
| WO2019014359A2 (en) * | 2017-07-12 | 2019-01-17 | The Scripps Research Institute | POLYMERASE CHAIN TRANSCRIPTION (PCT): EXPONENTIAL SYNTHESIS OF RNA AND MODIFIED RNA |
| US11425125B2 (en) * | 2020-06-24 | 2022-08-23 | Google Llc | Shared resource identification |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5610054A (en) | 1992-05-14 | 1997-03-11 | Ribozyme Pharmaceuticals, Inc. | Enzymatic RNA molecule targeted against Hepatitis C virus |
| US20030206887A1 (en) | 1992-05-14 | 2003-11-06 | David Morrissey | RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA) |
| US6174868B1 (en) | 1992-09-10 | 2001-01-16 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
| CA2145290C (en) * | 1992-09-28 | 2002-03-05 | Jang H. Han | Methods and compositions for controlling translation of hcv proteins |
| US6107027A (en) | 1994-12-14 | 2000-08-22 | University Of Washington | Ribozymes for treating hepatitis C |
| US6133246A (en) | 1997-08-13 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide compositions and methods for the modulation of JNK proteins |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| CA2363088A1 (en) * | 1999-02-11 | 2000-08-17 | Patrick T. Prendergast | Methods for treating viral infections |
| US8202979B2 (en) * | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
| WO2002081628A2 (en) | 2001-04-05 | 2002-10-17 | Ribozyme Pharmaceuticals, Incorporated | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies |
| US20040209831A1 (en) * | 2002-02-20 | 2004-10-21 | Mcswiggen James | RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA) |
| US20050209180A1 (en) | 2001-05-18 | 2005-09-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA) |
| ES2386775T3 (es) * | 2001-07-23 | 2012-08-30 | The Board Of Trustees Of The Leland Stanford Junior University | Procedimientos y composiciones para la inhibición mediada por ARNi de la expresión génica en mamíferos |
| US20030219823A1 (en) | 2001-09-07 | 2003-11-27 | Alsobrook John P. | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| US20080207542A1 (en) | 2002-03-26 | 2008-08-28 | Sirna Therapeutics, Inc. | RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA) |
| US20030191075A1 (en) * | 2002-02-22 | 2003-10-09 | Cook Phillip Dan | Method of using modified oligonucleotides for hepatic delivery |
| JP2005521393A (ja) * | 2002-03-20 | 2005-07-21 | マサチューセッツ インスティテュート オブ テクノロジー | Ｈｉｖ治療 |
| US7148342B2 (en) | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
| WO2004011647A1 (en) * | 2002-07-26 | 2004-02-05 | Chiron Corporation | Modified small interfering rna molecules and methods of use |
| NZ540779A (en) * | 2002-11-01 | 2008-05-30 | Univ Pennsylvania | Compositions and methods for siRNA inhibition of HIF-1 alpha |
| EP2305812A3 (en) | 2002-11-14 | 2012-06-06 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| DE602004028587D1 (de) | 2003-01-16 | 2010-09-23 | Univ Pennsylvania | ZUSAMMENSETZUNGEN UND VERFAHREN ZUR siRNA-HEMMUNG VON ICAM-1 |
| DE10302421A1 (de) * | 2003-01-21 | 2004-07-29 | Ribopharma Ag | Doppelsträngige Ribonukleinsäure mit verbesserter Wirksamkeit |
| US20050085528A1 (en) * | 2003-10-17 | 2005-04-21 | Pfizer Inc. | Parmaceutical |
| AU2005244827A1 (en) * | 2004-05-12 | 2005-12-01 | Jennifer Gordon | Compositions and methods for siRNA inhibition of primate polyomavirus genes |
| AR066984A1 (es) | 2007-06-15 | 2009-09-23 | Novartis Ag | Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia) |
| EP3000885B1 (en) | 2009-12-18 | 2018-07-25 | Arrowhead Pharmaceuticals, Inc. | Organic compositions to treat hsf1-related diseases |
-
2005
- 2005-09-30 ES ES05808592.9T patent/ES2441791T3/es not_active Expired - Lifetime
- 2005-09-30 JP JP2007534866A patent/JP2008514242A/ja active Pending
- 2005-09-30 CA CA2581651A patent/CA2581651C/en not_active Expired - Fee Related
- 2005-09-30 EP EP05808592.9A patent/EP1796732B1/en not_active Expired - Lifetime
- 2005-09-30 US US11/664,008 patent/US8138161B2/en not_active Expired - Fee Related
- 2005-09-30 WO PCT/US2005/035493 patent/WO2006039656A2/en not_active Ceased
-
2012
- 2012-03-12 JP JP2012054494A patent/JP2012105686A/ja active Pending
- 2012-09-03 JP JP2012193264A patent/JP2012255024A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012105686A5 (2) | ||
| HRP20210244T1 (hr) | Moduliranje eksprimiranja virusa hepatitisa b (hbv) | |
| Röthlisberger et al. | Aptamer chemistry | |
| de Haan et al. | Molecular interactions in the assembly of coronaviruses | |
| CN108136206B (zh) | 抗乙型肝炎病毒的组合物和药剂及其用途 | |
| Gottwein et al. | Cutting the gordian knot-development and biological relevance of hepatitis C virus cell culture systems | |
| JP2016520312A5 (2) | ||
| JP2017093448A5 (2) | ||
| JP2015518721A5 (2) | ||
| Merrill et al. | Seroprevalence of markers for hepatitis B viral infection | |
| JP2015501155A5 (2) | ||
| JP2009511034A5 (2) | ||
| JP2014511686A5 (2) | ||
| JP2020532961A5 (2) | ||
| Ojosnegros et al. | Quasispecies as a matter of fact: viruses and beyond | |
| Taylor | Host RNA circles and the origin of hepatitis delta virus | |
| JP2020500929A5 (2) | ||
| Flisiak et al. | siRNA drug development against hepatitis B virus infection | |
| RU2017121299A (ru) | ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК) | |
| JP2005518803A5 (2) | ||
| CN116514890A (zh) | 用于B型肝炎病毒感染的RNAi剂 | |
| RU2015151202A (ru) | Композиции и способы модулирования экспрессии hbv и ttr | |
| JP2015507625A5 (2) | ||
| JP2013537423A5 (2) | ||
| JP2012510297A5 (2) |